BMBlanka Míková

Blanka Míková

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Blanka Míková has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ales Linhart

    2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague

    1 shared publication
  • Amjad Bani-Hani

    32nd Department of Medicine - Department of Cardiovascular Medicine First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

    1 shared publication
  • David Ambrož

    2nd Department of Internal Medicine–Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic

    1 shared publication
  • Eduard Nemecek

    32nd Department of Medicine - Department of Cardiovascular Medicine First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

    1 shared publication
  • Hana Benakova

    Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

    1 shared publication
  • Magdalena Hodkova

    Department of Nephrology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study

    by Martina Peiskerová, Marta Kalousová, Vilem Danzig, Blanka Míková, Magdalena Hodková, Eduard Němeček, Amjad Bani-Hani, David Ambrož, Hana Benáková, Ales Linhart, et al.

    Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population. We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2–4. Mean follow-up was 36 ±10 months. Laboratory and echocardiographic data were collected 2–3 times, at the shortest interval of 12 months apart. Multivariate regression analysis was used to detect independent correlations of variables. Increased left ventricular mass index (LVMI, g/m2.7) was found in 29% patients with CKD 2–4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with CKD 2–4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial diameter, whereas a significant decrease in LVEF was noted. According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is more likely related to diastolic dysfunction in this population.